Researchers Investigate Cause of Contrast Agent Deposits in MS Patients
By MedImaging International staff writers Posted on 20 Dec 2016 |
Image: A comparison of MRI exams carried out with and without gadolinium-based contrast agents (Photo courtesy of Radiology Journal).
The results of a new study involving multiple sclerosis patients, show how performing repeated MRI scans on the patients with gadolinium-based contrast agents leads to the deposition of the agents in the brains of the scanning subjects.
The researchers from the Charité - Universitätsmedizin Berlin (Berlin, Germany) and the Max Delbrück Center for Molecular Medicine (Berlin, Germany) compared the use of linear and macrocyclic gadolinium-based MRI contrast agents, and how their use led to the deposition of the agents in multiple sclerosis patients’ brains.
The results of the study, published in the December 2016 issue of the journal Multiple Sclerosis, suggest that the use of 'macrocylcic contrast agents' reduces the risk of accumulation of the agents in the brain.
Study leader PD Dr. Michael Scheel, said, "Patients who received a different type of MRI contrast agent - one that is referred to as a macrocyclic contrast agent - showed no evidence of gadolinium brain deposition. Available data currently suggest that the risk of deposits is considerably higher with contrast agents that have a linear molecular structure. This effect appears to be absent, or much reduced, when using contrast agents with a ring-shaped, macrocyclic structure."
Related Links:
Charité - Universitätsmedizin Berlin
Max Delbrück Center for Molecular Medicine
The researchers from the Charité - Universitätsmedizin Berlin (Berlin, Germany) and the Max Delbrück Center for Molecular Medicine (Berlin, Germany) compared the use of linear and macrocyclic gadolinium-based MRI contrast agents, and how their use led to the deposition of the agents in multiple sclerosis patients’ brains.
The results of the study, published in the December 2016 issue of the journal Multiple Sclerosis, suggest that the use of 'macrocylcic contrast agents' reduces the risk of accumulation of the agents in the brain.
Study leader PD Dr. Michael Scheel, said, "Patients who received a different type of MRI contrast agent - one that is referred to as a macrocyclic contrast agent - showed no evidence of gadolinium brain deposition. Available data currently suggest that the risk of deposits is considerably higher with contrast agents that have a linear molecular structure. This effect appears to be absent, or much reduced, when using contrast agents with a ring-shaped, macrocyclic structure."
Related Links:
Charité - Universitätsmedizin Berlin
Max Delbrück Center for Molecular Medicine
Latest MRI News
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
- AI-Based MRI Tool Outperforms Current Brain Tumor Diagnosis Methods
- DW-MRI Lights up Small Ovarian Lesions like Light Bulbs
- Abbreviated Breast MRI Effective for High-Risk Screening without Compromising Diagnostic Accuracy
- New MRI Method Detects Alzheimer’s Earlier in People without Clinical Signs